US · ALUR
Allurion Technologies Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Natick, MA 01760
- Website
- allurion.com
Price · as of 2024-12-31
—
Market cap 9.09M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $181.45 | — |
| Intrinsic Value(DCF) | $0.97 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $350.60 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $243.75 | ||||
| 2022 | $256.00 | $301.36 | $19,042.70 | $0.00 | $0.00 |
| 2023 | $68.00 | $27.20 | $0.00 | $0.00 | $459.10 |
| 2024 | $2.43 | $181.45 | $0.00 | $0.00 | $350.60 |
AI valuation
Our deep-learning model estimates Allurion Technologies Inc.'s (ALUR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $181.45
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.97
— upside
Graham-Dodd
—
— upside
Graham Formula
$350.60
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALUR | Allurion Technologies Inc… | $1.17 | 9.09M | +15,409% | -17% | — | +29,866% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| AEMD | Aethlon Medical, Inc. | $2.01 | 1.53M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| COCH | Envoy Medical, Inc. | $0.72 | 15.07M | +3,147% | -23% | — | +2,867% | -1.16 | -1.39 | 116.08 | -2.03 | — | -1.39 | -229.78% | -8558.22% | -9242.22% | 217.79% | 381.46% | -226.68% | -1.04 | -23.60 | 1.24 | 0.84 | -0.72 | -4134.00% | -2880.00% | 977.00% | -72.47% | -2.38 | 374.98% | 9.37% | -10.90% | 9.37% | -2.09 | -2.13 | 179.09 | -39.33 |
| CODX | Co-Diagnostics, Inc. | $2.30 | 2.57M | +1,244% | +270% | — | +1,660% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| ERNA | Ernexa Therapeutics Inc. | $0.29 | 2.24M | +35,680% | +510% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| LFWD | Lifeward Ltd. | $7.40 | 11.28M | +6% | +25,985% | — | — | -0.49 | 0.75 | 0.55 | -0.32 | -1.71 | 1.25 | 32.01% | -76.19% | -112.78% | -88.56% | -118.09% | -61.79% | 0.05 | -152.76 | 2.08 | 1.27 | 0.24 | 2857.00% | 8524.00% | 468.00% | -153.36% | -2.12 | -131.16% | 0.00% | 0.00% | 0.00% | -0.41 | -0.37 | 0.32 | -12.27 |
| NVNO | enVVeno Medical Corporati… | $10.00 | 165.03K | — | — | — | — | -0.07 | 0.04 | — | 1.91 | — | 0.04 | 0.00% | — | — | -49.39% | -3781.90% | -46.63% | 0.03 | — | 20.88 | 20.60 | 0.03 | -3351.00% | — | -1067.00% | -1122.35% | -8.04 | -2678.57% | 0.00% | 0.00% | 0.00% | 1.70 | 2.41 | — | -5.04 |
| PRPH | ProPhase Labs, Inc. | $0.15 | 710.55K | +15,560% | +1,020% | — | +135,988% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
| VVOS | Vivos Therapeutics, Inc. | $1.40 | 8.25M | +1,347% | +8,020% | — | — | -1.66 | 2.33 | 1.23 | -1.31 | — | 3.91 | 60.00% | -74.32% | -74.09% | -266.25% | -562.91% | -85.62% | 0.19 | — | 1.50 | 1.34 | 0.45 | -8007.00% | 891.00% | 400.00% | -71.58% | -2.55 | -668.13% | 0.00% | 0.00% | 27.53% | -1.23 | -1.04 | 0.92 | -9.26 |
| XAIR | Beyond Air, Inc. | $0.96 | 4.87M | +6,086% | +58% | — | — | -0.27 | 0.95 | 3.47 | -0.42 | — | 1.04 | -44.89% | -1202.08% | -1258.43% | -250.98% | -332.73% | -111.42% | 0.86 | -14.75 | 3.20 | 1.56 | -0.17 | -6210.00% | 21967.00% | -2859.00% | -342.82% | -7.64 | -329.47% | 0.00% | 0.00% | 0.00% | -0.40 | -0.40 | 4.76 | -17.17 |
About Allurion Technologies Inc.
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
- CEO
- Shantanu K. Gaur
- Employees
- 134
- Beta
- -0.47
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.97 ÷ —) − 1 = — (DCF, example).